Combined, these data suggest that adropin has important effects on liver glucose metabolism, and may point to additional therapeutic avenues for this peptide in the control of metabolic dysfunction in obesity. This evidence concerns the gene ENHO and obesity due to melanocortin 4 receptor deficiency.